Eli Lilly

Drug Design, Drug Delivery & Technologies Xtalpi Inc. has entered into an artificial intelligence (AI) drug discovery collaboration with Eli Lilly & Co. The collaboration, valued at up to $250 million in upfront and milestone payments, will leverage Xtalpi’s integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an…

Biotech and pharma companies are evaluating how AI could make their businesses better. The CEO of Eli Lilly said he expects AI to massively change the productivity of the workplace. …

Partnership to focus on drug discovery platform. XtalPi, a pharmaceutical technology company, has announced an AI drug discovery collaboration with Eli Lilly, receiving up to $250 million in milestone payments. Per the agreement, XtalPi will utilize its robotics platform in order to deliver drug candidates for an undisclosed target. "With a closed loop of…

XtalPi’s autonomous labs, workstations and AGVs in Shenzhen and Shanghai. Credit: PRNewswire / XtalPi Inc. …

Pharmaceutical technology company XtalPi announced a collaboration with US drug maker Eli Lilly on Tuesday. The partnership will focus on using AI and robotics in drug discovery, with a significant upfront payment of up to $250 million. As part of this collaboration, XtalPi will utilize its ID4Inno™ small-molecule drug discovery platform, combining AI, autonomous labs,…

XtalPi’s artificial intelligence- and robotics-powered technologies have helped its pharmaceutical partners pinpoint dozens of small-molecule compounds that could potentially be further developed i | XtalPi’s artificial intelligence- and robotics-powered technologies have helped its pharmaceutical partners pinpoint dozens of small-molecule compounds that could potentially be further developed into novel therapeutics—and Eli Lilly wants a piece of…

Xtalpi operates autonomous labs in Shenzhen and Shanghai, with a new one in construction in ... [+] Cambridge, Massachusetts. Xtalpi Shenzhen-based Xtalpi, an AI-powered drug discoverer, announced Tuesday it has partnered with U.S. pharmaceutical giant Eli Lilly in a deal worth up to $250 million to unearth potential medicines for an undisclosed disease. Xtalpi…

CAMBRIDGE, Mass. , May 30, 2023 /PRNewswire/ -- Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities…

CAMBRIDGE, Mass. , May 30, 2023 /PRNewswire/ -- Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities…